ESCCardiology2019
ESC/EAS Guidelines for the Management of Dyslipidaemias 2019
Published by European Society of Cardiology · 78 pages · Class I
<1.4 mmol/LVery High Risk LDL
Class IPCSK9i indication
Class I add-onEzetimibe
Summary
Free previewDefines aggressive LDL-C targets for high and very high CV risk: <1.4 mmol/L (<55 mg/dL) for very high risk with ≥50% reduction. PCSK9 inhibitors recommended for patients not at target on maximum tolerated statin + ezetimibe. Updated risk calculator SCORE2 for European populations.
DyslipidaemiaLDL cholesterolStatinsPCSK9 inhibitorsSCORE2CV risk
Key Recommendations
Evidence Grading & Drug Doses
What's New vs Previous Version
Implementation & Clinical Pearls
Full guideline access requires an account
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Full guideline text with all recommendations
Evidence grades (Class I/II/III, Level A/B/C)
AI-generated summary and clinical pearls
Auto-logged as CPD/CME activity
Free plan includes 10 guideline reads per day · No credit card required